A randomized double - blind placebo - controlled cross - over trial of the impact on quality of life of continuing dexamethasone beyond 24   h following <font color="blue">adjuvant_2</font> <font color="blue">chemotherapy_2</font> <font color="blue">for_2</font> <font color="blue">breast_2</font> <font color="blue">cancer_2</font> <font color="blue">._2</font> 
<br>
<br> Uncertainty remains about the optimal anti - emetic regimen for control of delayed nausea and vomiting after adjuvant chemotherapy for breast cancer . <font color="blue">Many_1</font> <font color="blue">patients_1</font> <font color="blue">receive_1</font> <font color="blue">dexamethasone_1</font> <font color="blue">but_1</font> <font color="blue">complain_1</font> <font color="blue">of_1</font> <font color="blue">insomnia_1</font> <font color="blue">,_1</font> <font color="blue">anxiety_1</font> <font color="blue">/_1</font> <font color="blue">agitation_1</font> <font color="blue">,_1</font> <font color="blue">and_1</font> <font color="blue">indigestion_1</font> <font color="blue">._1</font> The aim was to determine if patients receiving chemotherapy for <font color="blue">breast_1</font> <font color="blue">cancer_1</font> prefer treatment with dexamethasone or placebo for prophylaxis against delayed nausea and vomiting , and to compare quality of life ( QOL ) between the two treatments . In this randomized , double - blind , cross - over trial , we compared oral dexamethasone ( 4   mg twice daily for 2   days ) versus placebo for <font color="blue">chemotherapy_3</font> <font color="blue">-_3</font> <font color="blue">naïve_3</font> <font color="blue">patients_3</font> <font color="blue">with_3</font> <font color="blue">breast_3</font> <font color="blue">cancer_3</font> <font color="blue">._3</font> All <font color="blue">patients_1</font> received intravenous granisetron and dexamethasone pre - chemotherapy and oral granisetron on day 2 . Primary endpoints were : ( i ) patient preference ; ( ii ) difference between cycles in change of QOL from days 1 to 8 . <font color="blue">Median_3</font> <font color="blue">age_3</font> <font color="blue">of_3</font> <font color="blue">the_3</font> <font color="blue">94_5</font> <font color="blue">women_5</font> <font color="blue">was_5</font> <font color="blue">51_5</font> <font color="blue"> _5</font> <font color="blue">years_5</font> <font color="blue">(_5</font> <font color="blue">range_5</font> <font color="blue">27_5</font> <font color="blue">-_5</font> <font color="blue">76_5</font> <font color="blue">)_5</font> <font color="blue">:_5</font> <font color="blue">79_3</font> <font color="blue">received_2</font> <font color="blue">fluorouracil_2</font> <font color="blue">/_2</font> <font color="blue">epirubicin_2</font> <font color="blue">/_2</font> <font color="blue">cyclophosphamide_2</font> <font color="blue">and_1</font> <font color="blue">15_2</font> <font color="blue">received_2</font> <font color="blue">doxorubicin_2</font> <font color="blue">/_2</font> <font color="blue">cyclophosphamide_2</font> <font color="blue">._2</font> Thirteen withdrew pre - cycle 2 with no differences between arms . Of <font color="blue">80_1</font> <font color="blue">patients_1</font> stating a preference , <font color="blue">31_1</font> <font color="blue">preferred_1</font> <font color="blue">placebo_1</font> ( 39   % , 95   % CI : 28 - 50   % ) and <font color="blue">37_1</font> <font color="blue">(_1</font> <font color="blue">46_1</font> <font color="blue"> _1</font> <font color="blue">%_1</font> <font color="blue">,_1</font> <font color="blue">95_1</font> <font color="blue"> _1</font> <font color="blue">%_1</font> <font color="blue">CI_1</font> <font color="blue">:_1</font> <font color="blue">35_1</font> <font color="blue">-_1</font> <font color="blue">58_1</font> <font color="blue"> _1</font> <font color="blue">%_1</font> <font color="blue">)_1</font> <font color="blue">preferred_1</font> <font color="blue">dexamethasone_1</font> <font color="blue">;_1</font> <font color="blue">12_1</font> <font color="blue">had_1</font> <font color="blue">no_1</font> <font color="blue">preference_1</font> <font color="blue">._1</font> There were no differences in intensity of vomiting , nausea , or time to onset of vomiting . There was greater decrease in global QOL ( p   =   0.06 ) when patients received dexamethasone . No other symptom / QOL domains differed significantly . In conclusion , no significant difference was found in patient preference , QOL , or symptoms regardless of whether dexamethasone or placebo was used after adjuvant chemotherapy .